Nature Search

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

During an ongoing Ebola virus outbreak, infection before onset of protective immunity from vaccination is a possible scenario. Here the authors show in non-human primates that vaccination shortly before treatment with a monoclonal antibody does not negatively affect effectiveness of the antibody therapy.

Robert W. Cross
Zachary A. Bornholdt
Thomas W. Geisbert
ResearchOpen Access27 Jul 2020
Nature Communications

Volume: 11, P: 1-8
Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus

Prasad et al. assess four therapeutics in preventing lethal disease in an established nonhuman primate model of Ebola virus infection. They find that each therapy results in ~ 40% survival, suggesting the use of alternative strategies, such as combining therapeutics to combat Ebola.

Abhishek N. Prasad
Courtney Woolsey
Thomas W. Geisbert
ResearchOpen Access23 Apr 2025
Nature Communications

Volume: 16, P: 1-13
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates

The oral drug obeldesivir confers 80% survival when given after lethal Marburg virus exposure in cynomolgus macaques and also delays viral replication and disease onset, suggesting a potential treatment option for an infection with no approved therapies.

Robert W. Cross
Courtney Woolsey
Thomas W. Geisbert
ResearchOpen Access13 Jan 2025
Nature Medicine

Volume: 31, P: 1303-1311
Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins

Structural and functional characterization of two neutralizing antibodies that target conserved, nonoverlapping epitopes in HeV and NiV F protein trimers and inhibit membrane fusion establishes the therapeutic potential of antibody cocktails to protect against henipavirus infection.

Ha V. Dang
Robert W. Cross
David Veesler
Research29 Apr 2021
Nature Structural & Molecular Biology

Volume: 28, P: 426-434
Establishment of an African green monkey model for COVID-19 and protection against re-infection

Geisbert and colleagues report that African green monkeys infected with the SARS-CoV-2 virus develop disease symptoms that closely resemble those seen in infected humans, making this animal model a useful surrogate to investigate immune responses to coronavirus infection.

Courtney Woolsey
Viktoriya Borisevich
Robert W. Cross
Research24 Nov 2020
Nature Immunology

Volume: 22, P: 86-98
Combination therapy protects macaques against advanced Marburg virus disease

Extending the therapeutic window for acute viral infections could save lives. Here, the authors show that combination treatment with a human monoclonal antibody and remdesivir initiated at 6 days post infection with Marburg virus provides 80% protection in non-human primates.

Robert W. Cross
Zachary A. Bornholdt
Thomas W. Geisbert
ResearchOpen Access25 Mar 2021
Nature Communications

Volume: 12, P: 1-10
Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Thomas Geisbert and colleagues show that a cocktail of monoclonal antibodies protects cynomolgus monkeys from lethal Lassa fever virus infection, including when administration is delayed by more than a week after viral challenge.

Chad E Mire
Robert W Cross
Thomas W Geisbert
Research04 Sept 2017
Nature Medicine

Volume: 23, P: 1146-1149
Natural history of nonhuman primates after conjunctival exposure to Ebola virus

Robert W. Cross
Abhishek N. Prasad
Thomas W. Geisbert
ResearchOpen Access13 Mar 2023
Scientific Reports

Volume: 13, P: 1-12
Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages

Megan L. Heinrich
Matthew L. Boisen
Luis M. Branco
ResearchOpen Access29 Sept 2020
Scientific Reports

Volume: 10, P: 1-19
A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus

Thomas W. Geisbert
Kathryn Bobb
Antony S. Dimitrov
ResearchOpen Access08 Feb 2021
npj Vaccines

Volume: 6, P: 1-12
Immune correlates of postexposure vaccine protection against Marburg virus

Courtney Woolsey
Allen Jankeel
Thomas W. Geisbert
ResearchOpen Access20 Feb 2020
Scientific Reports

Volume: 10, P: 1-18
Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model

Benjamin A. Satterfield
Viktoriya Borisevich
Chad E. Mire
ResearchOpen Access13 Nov 2019
Scientific Reports

Volume: 9, P: 1-18
Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy

Chad E. Mire
Benjamin A. Satterfield
Thomas W. Geisbert
ResearchOpen Access03 Aug 2016
Scientific Reports

Volume: 6, P: 1-16

Search

Filter By:

Search

Quick links